Years Ended December 31 | 2013 | 2012 | 2011 | ||||||||
Segment profits: | |||||||||||
Pharmaceutical segment | $ | 22,983 | $ | 25,852 | $ | 25,617 | |||||
Other segments | 3,094 | 3,163 | 2,995 | ||||||||
Total segment profits | 26,077 | 29,015 | 28,612 | ||||||||
Other profits (losses) | 19 | 26 | (11 | ) | |||||||
Unallocated: | |||||||||||
Interest income | 264 | 232 | 145 | ||||||||
Interest expense | (801 | ) | (714 | ) | (695 | ) | |||||
Equity income from affiliates | (159 | ) | 102 | 41 | |||||||
Depreciation and amortization | (2,250 | ) | (2,059 | ) | (2,412 | ) | |||||
Research and development | (6,381 | ) | (7,126 | ) | (7,251 | ) | |||||
Amortization of purchase accounting adjustments | (4,690 | ) | (4,872 | ) | (5,000 | ) | |||||
Restructuring costs | (1,709 | ) | (664 | ) | (1,306 | ) | |||||
Net charge related to settlement of ENHANCE Litigation | — | (493 | ) | — | |||||||
Arbitration settlement charge | — | — | (500 | ) | |||||||
Other unallocated, net | (4,825 | ) | (4,708 | ) | (4,289 | ) | |||||
$ | 5,545 | $ | 8,739 | $ | 7,334 |